Ionis Presents New Data from NEURO-TTR Study at European ATTR Amyloidosis Meeting

Significant benefit in quality of life and disease severity endpoints observed in inotersen-treated patients compared to placebo-treated patients Consistent and significant differences observed between inotersen-treated and placebo-treated patients independent of disease stage, types of mutation, previous use of TTR stabilizers or presence of cardiomyopathy Encouraging benefit observed across multiple cardiac measures in inotersen-treated patients with significant cardiac disease compared to placebo-treated patients Conference call and webcast on Thursday, November 2, 7:00 a.m. ET at www.ionispharma.com CARLSBAD, Calif., Nov. 2, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced new data from the Phase 3 NEURO-TTR study, evaluating inotersen in patients with hereditary TTR amyloidosis (hATTR). Results from the study demonstrated early and significant benefit in both co-primary endpoints: Norfolk Quality of Life Questionnaire-Diabetic Neuropathy (Norfolk QoL-DN) and modified Neuropathy Impairment Score +7 (mNIS+7), a measure of neuropathic disease progression, in inotersen-treated patients compared to placebo-treated. A continued increase in benefit, relative to placebo, was observed in both endpoints through study completion. Statistically significant benefit was also observed in multiple other endpoints in the study, including the SF-36 Health Survey and cardiac measures. The data will be presented at the first annual meeting of the ATTR Amyloidosis Meeting in Paris, France.

The release as fetched from its publisher. ionis.com ↗